Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial.Circulation · 2024
   Trial
2. The Heart-Brain Axis in the Context of Cardiovascular Disease.Physiology (Bethesda, Md.) · 2026
   Review
3. The preventive effect of sodium-glucose co-transporter-2 inhibitors on life-threatening arrhythmias in patients with chronic kidney disease: a meta-analysis.Frontiers in cardiovascular medicine · 2026
   Review
4. Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
   Review
5. Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes.Life (Basel, Switzerland) · 2025
   Article
6. The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure.Biomedicines · 2025
   Review
7. Association between Life's Crucial 9 and Cardiorenal syndrome: the mediating role of weight-adjusted-waist index.Frontiers in nutrition · 2025
   Article
8. Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.Advances in therapy · 2024
   Review
9. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.Journal of cardiovascular translational research · 2022
   Review
10. Renoprotective Effects of SGLT2 Inhibitors.Heart failure clinics · 2022
    Review
11. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study.Frontiers in cardiovascular medicine · 2022
    Article
12. Mechanisms and Models in Heart Failure: A Translational Approach.Circulation research · 2021
    Review
13. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.Annual review of physiology · 2021
    Review
14. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.Diabetes, obesity & metabolism · 2021
    Observational
15. Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis.Metabolism open · 2020
    Article
16. Natriuresis, Diuresis, and Volume Changes in Diabetics With Heart Failure With Preserved Ejection Fraction: Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Natriuretic Peptides.Journal of the American Heart Association · 2020
    Article

Corrections and comments

• Comment on
  SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as